The AI engine is offline (last seen Aug 12, 05:02 UTC). Scores are shown as of their timestamps; new theses and refreshes are queued and run the moment it returns.

Macro

Search catalysts, news stories, and pressures, or browse the trust-weighted news feed below.

Home tech energy finance healthcare defense industrial consumer communication utilities real estate raw materials
← back
healthcare · sector mood
2011
year mood +0.10 · -0.17 to +0.20 across 12 mo
Monthly mood
bearish −1 +1 bullish
-0.25 -0.12 0 +0.12 +0.25 Jan +0.20 Feb Mar Apr May Jun Jul Aug Sep Oct Nov -0.17 Dec
month values ▾
JanFebMarAprMayJunJulAugSepOctNovDec
+0.20+0.12+0.20+0.20+0.10+0.10+0.10+0.10+0.10+0.10-0.17+0.10

The patent cliff peaked with Lipitor's November expiry, eroding big-pharma revenue, but the sector stayed a defensive anchor in the year's debt-ceiling and eurozone turmoil while FDA approvals began reviving.

How this mood is scored ▾
Each day the model reads that day's news for the sector and asks, as someone who owns assets or makes their living in it: how am I feeling this month, and why? The month's mood is that running answer, tied to the specific events driving it (the story shown above). It leans on trusted, higher-impact reporting, and on the prior month when a month is quiet, so one loud headline can't swing it. The read updates daily through the month; once a month ends, its mood is locked. This year is read live from the news the pipeline actually collected (hover a bar for its story count). · last computed Jul 11, 2026
Top healthcare stories of 2011
Feb
Sanofi acquires Genzyme for $20.1B to bolster rare-disease drug pipeline deseret.com →

Sanofi is acquiring U.S. biotech firm Genzyme for $20.1 billion to strengthen its portfolio of high-margin, patent-protected rare-disease treatments amid declining sales from patent expirations. The deal includes contingent payments tied to drug production and approvals, reflecting confidence in Genzyme's specialty therapies. The acquisition signals a strategic shift in big pharma toward orphan drugs as a growth engine with limited generic competition.

Nov
Best-selling drug of all time loses U.S. patent as generic Lipitor launches pbs.org →

On November 30, 2011, U.S. patent protection expired on Lipitor (atorvastatin), the cholesterol pill that at its peak generated about $10.7 billion in annual sales and stands as the best-selling drug in history. The launch of generic atorvastatin, alongside a cluster of other blockbuster expirations, marked the height of the pharmaceutical 'patent cliff,' with the brand's U.S. sales falling roughly 79% within a year.